{"name":"GE HealthCare Technologies","slug":"ge-healthcare","ticker":"GEHC","exchange":"NASDAQ","domain":"gehealthcare.com","description":"GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, X-ray systems, and women's health products. The AVS segment provides ultrasound, image guided therapies, and interventional solutions for screening, diagnosis, treatment, and monitoring of certain diseases in clinical areas, such as women's health, cardiovascular, and comprehensive care ultrasound as well as surgical visualization and guidance products. The PCS segment provides medical devices, consumables, services, and digital solutions. Its portfolio includes ","hq":"Chicago, IL","founded":0,"employees":"54000","ceo":"Peter Arduini","sector":"MedTech","stockPrice":73.05,"stockChange":3.32,"stockChangePercent":4.76,"marketCap":"$33.3B","metrics":{"revenue":20625000000,"revenueGrowth":7.1,"grossMargin":40,"rdSpend":1260000000,"netIncome":2084000000,"cash":4492000256,"dividendYield":20,"peRatio":16.1,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"1973-01-01","label":"Metrizoate first approved","drug":"Metrizoate","drugSlug":"metrizoic-acid","type":"approval","sentiment":"positive"},{"date":"1985-01-01","label":"Omnipaque 180 first approved","drug":"Omnipaque 180","drugSlug":"iohexol","type":"approval","sentiment":"positive"},{"date":"1988-01-01","label":"Ceretec first approved","drug":"Ceretec","drugSlug":"technetium-tc-99m-exametazime","type":"approval","sentiment":"positive"},{"date":"1993-01-01","label":"Omniscan first approved","drug":"Omniscan","drugSlug":"gadodiamide","type":"approval","sentiment":"positive"},{"date":"1996-01-01","label":"Visipaque 270 first approved","drug":"Visipaque 270","drugSlug":"iodixanol","type":"approval","sentiment":"positive"},{"date":"1996-01-01","label":"Myoview first approved","drug":"Myoview","drugSlug":"technetium-tc-99m-tetrofosmin","type":"approval","sentiment":"positive"},{"date":"2008-01-01","label":"Adreview first approved","drug":"Adreview","drugSlug":"iobenguane-123i","type":"approval","sentiment":"positive"},{"date":"2013-01-01","label":"Vizamyl first approved","drug":"Vizamyl","drugSlug":"flutemetamol-18f","type":"approval","sentiment":"positive"},{"date":"2013-01-01","label":"Vizamyl first approved","drug":"Vizamyl","drugSlug":"flutemetamol","type":"approval","sentiment":"positive"},{"date":"2020-01-01","label":"Cerianna first approved","drug":"Cerianna","drugSlug":"fluoroestradiol-f-18","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-06-01","label":"Perflutren Protein-Type A Microspheres Injectable Suspension patent cliff ($1.2B at risk)","drug":"Perflutren Protein-Type A Microspheres Injectable Suspension","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":14,"colorKey":"oncology","drugs":[{"name":"MPI INDIUM DTPA IN 111","genericName":"INDIUM IN-111 PENTETATE DISODIUM","slug":"indium-in-111-pentetate-disodium","indication":"Other","status":"marketed"},{"name":"Visipaque 270","genericName":"IODIXANOL","slug":"iodixanol","indication":"Other","status":"marketed"},{"name":"Adreview","genericName":"iobenguane (123I)","slug":"iobenguane-123i","indication":"Other","status":"marketed"},{"name":"Clariscan","genericName":"Clariscan","slug":"clariscan","indication":"Other","status":"marketed"},{"name":"Gadodiamide Injection","genericName":"Gadodiamide Injection","slug":"gadodiamide-injection","indication":"Contrast enhancement for magnetic resonance imaging of the central nervous system","status":"phase_3"},{"name":"SonoVue®","genericName":"SonoVue®","slug":"sonovue","indication":"Enhanced ultrasound imaging of the liver, spleen, and other organs","status":"phase_3"},{"name":"GE-145","genericName":"GE-145","slug":"ge-145","indication":"Other","status":"phase_2"},{"name":"Iopamidol 300-Arm 2","genericName":"Iopamidol 300-Arm 2","slug":"iopamidol-300-arm-2","indication":"Other","status":"marketed"},{"name":"Metrizoate","genericName":"METRIZOIC ACID","slug":"metrizoic-acid","indication":"Other","status":"marketed"},{"name":"Myoview","genericName":"TECHNETIUM TC 99M TETROFOSMIN","slug":"technetium-tc-99m-tetrofosmin","indication":"Radionuclide myocardial perfusion study","status":"marketed"},{"name":"Omnipaque 180","genericName":"IOHEXOL","slug":"iohexol","indication":"Other","status":"marketed"},{"name":"Omniscan","genericName":"Omniscan","slug":"omniscan","indication":"Magnetic resonance imaging","status":"marketed"},{"name":"Omniscan","genericName":"GADODIAMIDE","slug":"gadodiamide","indication":"Magnetic resonance imaging","status":"marketed"},{"name":"Vizamyl","genericName":"Flutemetamol (18F)","slug":"flutemetamol-18f","indication":"Positron emission tomography","status":"marketed"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":7,"colorKey":"cardiovascular","drugs":[{"name":"Iodixanol, Ioversol, Iopromide","genericName":"Iodixanol, Ioversol, Iopromide","slug":"iodixanol-ioversol-iopromide","indication":"Coronary angiography and percutaneous coronary intervention","status":"marketed"},{"name":"Pharmacological stress agents","genericName":"Pharmacological stress agents","slug":"pharmacological-stress-agents","indication":"Diagnostic imaging agent for assessment of myocardial perfusion and coronary artery disease","status":"phase_3"},{"name":"Iodixanol 320-Arm 1","genericName":"Iodixanol 320-Arm 1","slug":"iodixanol-320-arm-1","indication":"Coronary angiography and percutaneous coronary intervention","status":"marketed"},{"name":"PET MPI","genericName":"PET MPI","slug":"pet-mpi","indication":"Myocardial perfusion imaging for detection and assessment of coronary artery disease","status":"phase_3"},{"name":"SPECT MPI","genericName":"SPECT MPI","slug":"spect-mpi","indication":"Detection of coronary artery disease and myocardial ischemia","status":"phase_3"},{"name":"Technetium Tc99m Tetrofosmin injections","genericName":"Technetium Tc99m Tetrofosmin injections","slug":"technetium-tc99m-tetrofosmin-injections","indication":"Acute coronary syndrome and myocardial infarction imaging","status":"marketed"},{"name":"Thallous Chloride T1-201","genericName":"Thallous Chloride T1-201","slug":"thallous-chloride-t1-201","indication":"Myocardial perfusion imaging for detection of coronary artery disease","status":"marketed"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"immunology","drugs":[{"name":"Iobenguane I -123 Injection","genericName":"Iobenguane I -123 Injection","slug":"iobenguane-i-123-injection","indication":"Diagnostic imaging of neuroendocrine tumors, including pheochromocytoma and paraganglioma","status":"phase_3"},{"name":"Cerianna","genericName":"FLUOROESTRADIOL F-18","slug":"fluoroestradiol-f-18","indication":"Detection of ER-positive lesions in breast cancer","status":"marketed"},{"name":"I-123 mIBG","genericName":"I-123 mIBG","slug":"i-123-mibg","indication":"Thyroid cancer","status":"phase_2"},{"name":"Sonazoid™","genericName":"Sonazoid™","slug":"sonazoid","indication":"Liver cancer diagnosis and monitoring","status":"phase_3"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"neuroscience","drugs":[{"name":"Ceretec","genericName":"TECHNETIUM TC 99M EXAMETAZIME","slug":"technetium-tc-99m-exametazime","indication":"Detection of altered cerebral perfusion in stroke","status":"marketed"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"infectious","drugs":[{"name":"Vizamyl","genericName":"FLUTEMETAMOL","slug":"flutemetamol","indication":"Alzheimer's disease","status":"marketed"}]}],"pipeline":[{"name":"MPI INDIUM DTPA IN 111","genericName":"INDIUM IN-111 PENTETATE DISODIUM","slug":"indium-in-111-pentetate-disodium","phase":"marketed","mechanism":"","indications":[],"catalyst":""},{"name":"Visipaque 270","genericName":"IODIXANOL","slug":"iodixanol","phase":"marketed","mechanism":"Visipaque 270 works by increasing the density of fluids in the body, making them visible on X-ray images.","indications":[],"catalyst":""},{"name":"Adreview","genericName":"iobenguane (123I)","slug":"iobenguane-123i","phase":"marketed","mechanism":"Adreview works by binding to specific cells or tissues in the body, allowing for imaging and diagnosis.","indications":[],"catalyst":""},{"name":"Clariscan","genericName":"Clariscan","slug":"clariscan","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Gadodiamide Injection","genericName":"Gadodiamide Injection","slug":"gadodiamide-injection","phase":"phase_3","mechanism":"Gadodiamide is a gadolinium-based contrast agent that enhances magnetic resonance imaging by shortening the T1 relaxation time of water protons in tissues.","indications":["Contrast enhancement for magnetic resonance imaging of the central nervous system","Contrast enhancement for magnetic resonance imaging of the body"],"catalyst":""},{"name":"Iobenguane I -123 Injection","genericName":"Iobenguane I -123 Injection","slug":"iobenguane-i-123-injection","phase":"phase_3","mechanism":"Iobenguane I-123 is a radiolabeled norepinephrine analog that accumulates in neuroendocrine tumors and the sympathetic nervous system, allowing for diagnostic imaging via single-photon emission computed tomography (SPECT).","indications":["Diagnostic imaging of neuroendocrine tumors, including pheochromocytoma and paraganglioma","Imaging of neuroblastoma in pediatric patients"],"catalyst":""},{"name":"Iodixanol, Ioversol, Iopromide","genericName":"Iodixanol, Ioversol, Iopromide","slug":"iodixanol-ioversol-iopromide","phase":"marketed","mechanism":"These are iodinated contrast media that increase radiodensity to enhance visualization of blood vessels and organs during imaging procedures.","indications":["Coronary angiography and percutaneous coronary intervention","Peripheral vascular angiography","Cerebral angiography","Renal angiography","Computed tomography imaging enhancement"],"catalyst":""},{"name":"Pharmacological stress agents","genericName":"Pharmacological stress agents","slug":"pharmacological-stress-agents","phase":"phase_3","mechanism":"Pharmacological stress agents induce controlled cardiac stress through vasodilation or increased heart rate to assess myocardial perfusion and function during diagnostic imaging.","indications":["Diagnostic imaging agent for assessment of myocardial perfusion and coronary artery disease","Evaluation of cardiac function in patients unable to perform exercise stress testing"],"catalyst":""},{"name":"SonoVue®","genericName":"SonoVue®","slug":"sonovue","phase":"phase_3","mechanism":"SonoVue is a microbubble ultrasound contrast agent that enhances ultrasound imaging.","indications":["Enhanced ultrasound imaging of the liver, spleen, and other organs"],"catalyst":""},{"name":"Ceretec","genericName":"TECHNETIUM TC 99M EXAMETAZIME","slug":"technetium-tc-99m-exametazime","phase":"marketed","mechanism":"Small molecule","indications":["Detection of altered cerebral perfusion in stroke","Localization of intra-abdominal infection and inflammatory bowel disease"],"catalyst":""},{"name":"Cerianna","genericName":"FLUOROESTRADIOL F-18","slug":"fluoroestradiol-f-18","phase":"marketed","mechanism":"Cerianna works by binding to estrogen receptors in the body, allowing for imaging of these receptors through positron emission tomography.","indications":["Detection of ER-positive lesions in breast cancer"],"catalyst":""},{"name":"GE-145","genericName":"GE-145","slug":"ge-145","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"I-123 mIBG","genericName":"I-123 mIBG","slug":"i-123-mibg","phase":"phase_2","mechanism":"I-123 mIBG binds to norepinephrine transporters","indications":["Thyroid cancer"],"catalyst":""},{"name":"Iodixanol 320-Arm 1","genericName":"Iodixanol 320-Arm 1","slug":"iodixanol-320-arm-1","phase":"marketed","mechanism":"Iodixanol is a non-ionic, iso-osmolar contrast medium that provides radiographic visualization of blood vessels and organs during diagnostic imaging procedures.","indications":["Coronary angiography and percutaneous coronary intervention","Peripheral vascular angiography","Renal artery imaging","General vascular and cardiac imaging procedures"],"catalyst":""},{"name":"Iopamidol 300-Arm 2","genericName":"Iopamidol 300-Arm 2","slug":"iopamidol-300-arm-2","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Metrizoate","genericName":"METRIZOIC ACID","slug":"metrizoic-acid","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Myoview","genericName":"TECHNETIUM TC 99M TETROFOSMIN","slug":"technetium-tc-99m-tetrofosmin","phase":"marketed","mechanism":"Myoview works by accumulating in the heart muscle and emitting gamma rays that are detected by a scanner, allowing for visualization of blood flow.","indications":["Radionuclide myocardial perfusion study"],"catalyst":""},{"name":"Omnipaque 180","genericName":"IOHEXOL","slug":"iohexol","phase":"marketed","mechanism":"Omnipaque 180 works by being injected into the bloodstream, where it accumulates in body tissues and enhances the contrast of X-rays.","indications":[],"catalyst":""},{"name":"Omniscan","genericName":"Omniscan","slug":"omniscan","phase":"marketed","mechanism":"Small molecule","indications":["Magnetic resonance imaging"],"catalyst":""},{"name":"Omniscan","genericName":"GADODIAMIDE","slug":"gadodiamide","phase":"marketed","mechanism":"Small molecule","indications":["Magnetic resonance imaging"],"catalyst":""},{"name":"PET MPI","genericName":"PET MPI","slug":"pet-mpi","phase":"phase_3","mechanism":"PET MPI is a myocardial perfusion imaging agent that uses a radioactive tracer to visualize blood flow to the heart muscle during stress and rest conditions.","indications":["Myocardial perfusion imaging for detection and assessment of coronary artery disease","Evaluation of myocardial viability in patients with prior myocardial infarction"],"catalyst":""},{"name":"SPECT MPI","genericName":"SPECT MPI","slug":"spect-mpi","phase":"phase_3","mechanism":"SPECT MPI is a diagnostic imaging agent that uses technetium-99m labeled tracers to visualize myocardial perfusion and detect areas of reduced blood flow in the heart.","indications":["Detection of coronary artery disease and myocardial ischemia","Assessment of myocardial viability post-infarction","Risk stratification in patients with known or suspected coronary artery disease"],"catalyst":""},{"name":"Sonazoid™","genericName":"Sonazoid™","slug":"sonazoid","phase":"phase_3","mechanism":"Sonazoid is a liver-specific contrast agent that enhances the visibility of liver lesions during MRI.","indications":["Liver cancer diagnosis and monitoring","Liver lesion detection"],"catalyst":""},{"name":"Technetium Tc99m Tetrofosmin injections","genericName":"Technetium Tc99m Tetrofosmin injections","slug":"technetium-tc99m-tetrofosmin-injections","phase":"marketed","mechanism":"Technetium Tc99m Tetrofosmin is a lipophilic cationic complex that accumulates in viable myocardial tissue based on blood flow and mitochondrial membrane potential, allowing visualization of myocardial perfusion.","indications":["Acute coronary syndrome and myocardial infarction imaging","Coronary artery disease detection via stress testing","Myocardial viability assessment"],"catalyst":""},{"name":"Thallous Chloride T1-201","genericName":"Thallous Chloride T1-201","slug":"thallous-chloride-t1-201","phase":"marketed","mechanism":"Thallous chloride T1-201 is a potassium analog that accumulates in viable myocardial tissue and is used as a radiotracer for cardiac imaging.","indications":["Myocardial perfusion imaging for detection of coronary artery disease","Assessment of myocardial viability in patients with coronary artery disease"],"catalyst":""},{"name":"Vizamyl","genericName":"Flutemetamol (18F)","slug":"flutemetamol-18f","phase":"marketed","mechanism":"Vizamyl works by binding to amyloid beta A4 protein in the brain, allowing for visualization of amyloid deposits in PET imaging.","indications":["Positron emission tomography"],"catalyst":""},{"name":"Vizamyl","genericName":"FLUTEMETAMOL","slug":"flutemetamol","phase":"marketed","mechanism":"Vizamyl works by binding to amyloid plaques in the brain, allowing for visualization through positron emission tomography (PET) imaging.","indications":["Alzheimer's disease","other causes of cognitive decline","Alzheimer's disease","other causes of cognitive decline"],"catalyst":""}],"recentEvents":[{"date":"2023-06-01","type":"deal","headline":"GE HealthCare to be acquired by Stryker for $21.5 billion","summary":"GE HealthCare Technologies has agreed to be acquired by Stryker in an all-cash transaction valued at $21.5 billion.","drugName":"","sentiment":"positive"},{"date":"2022-11-14","type":"regulatory","headline":"FDA Approves GE HealthCare's Clariscan","summary":"The US FDA has approved GE HealthCare's Clariscan, a contrast agent for magnetic resonance imaging (MRI).","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiXkFVX3lxTE5qUU5GMDdac3l3TTkxd0JUSDlwZmZlV3p5RjVlTEZQWUwwZWhwU2pGNWNDRE9KTWNsYmJRdzJLS1ZxcDZLbmduOWppSXA3MjJaSEo5WU1CTUZaT1FzRVHSAWNBVV95cUxQakRCUDM1X3ZwVkhraC1zNHBCb1gxTElMSHBVTmhoTm9DSkgwdjNlV1ZFSHBZb0tNWXJVbWZPcDRpSC1fX25pdU1PUndHaDRLQ01mT3l0YUEtU3dxcHg3QktUckE?oc=5","date":"2026-03-24","type":"pipeline","source":"Bitget","summary":"Reasons to Keep GEHC Shares in Your Investment Portfolio at This Time - Bitget","headline":"Reasons to Keep GEHC Shares in Your Investment Portfolio at This Time","sentiment":"neutral"},{"date":"2026-03-17","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE53Ulc0MVRkanRrTk40aHM3OVZvMGVnbjZsNlBIdldiTGhNSW50Q2Vkel9nbVlTWks5SWVvSUMxTVM5YTR5a0FuMDV5WEhQSnRUUG1pTTZYbmJUcWhaSS1yaFZMZG5kZmxBaU5oUkZn?oc=5","date":"2026-03-05","type":"deal","source":"Morningstar","summary":"The Best Healthcare Stocks to Buy - Morningstar","headline":"The Best Healthcare Stocks to Buy","sentiment":"neutral"},{"date":"2026-02-27","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxPVURPRk5NbnlIMzFBT2laZ2lqb3JpYmdFTWkwRU5IS0pjMVBGQnhGLTNFZzhhbEY0X2xYX2JvQWswc3RMTFkzZGhEajVRVjB1RjhvbVpLNmF3TE9pcWVtclJDRC1nSHNJNkN1VHhnb0hzd2tiYXVobldGWHA2dVBhUEhCeXFqUi1zUUpxeDg4RUhXWXF5ZUtMSy0tVHFVTHlxR2cyMkpwZFl5T08wcktZMk1JU0k2UlE?oc=5","date":"2026-02-23","type":"regulatory","source":"Finviz","summary":"GE HealthCare Technologies Inc. (GEHC) Positioned to Capitalize on Strong Demand Backlog - Finviz","headline":"GE HealthCare Technologies Inc. (GEHC) Positioned to Capitalize on Strong Demand Backlog","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxNcTVUQ0ZxYVFjYjB0czFFaFF6SmwyN0ljeTRjSmY3TTQzTWRoWE1rcm1VcGt3b0p3dnIzMDJDb3doZUpFVXViejdYR0V0LW5WRmhlTmo0YXRoTUlIbHhINW9sX19Uc0F0bXRlcmttOG5BcWtSZzFjNGl4dERBWlhNa0pOZGxfa3dKWDFuaWZFV196OG1l?oc=5","date":"2026-02-23","type":"pipeline","source":"Finviz","summary":"1 Healthcare Stock to Consider Right Now and 2 We Turn Down - Finviz","headline":"1 Healthcare Stock to Consider Right Now and 2 We Turn Down","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxPOXhoZ2pMNUExQUt5RGZHbThsQ3pjMDRRZWRZaFB2OWlKQUJ2Ql9lWXc3MC0wcXlQWTNmdm5ZY2ZXdEl6ZDdTNEJ5cm82X2dMOE5hOWM1bGFfRWozYVBhTGR2N1VDaVhlWnRONjhTX0NuM25xdFp1SDNFUXhiU0ZGbF9RN2hpVV9TV1NmWjdOOEF0RzlyQTBSRHBsaXd0eUx6Qk1nUTV1S1pPd0FrZTY0YW5IaTdtdw?oc=5","date":"2026-02-04","type":"earnings","source":"TradingView","summary":"GE HealthCare’s (NASDAQ:GEHC) Q4 CY2025: Beats On Revenue - TradingView","headline":"GE HealthCare’s (NASDAQ:GEHC) Q4 CY2025: Beats On Revenue","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxNYjF2MDFTYU10RFdGclhodkg2Ymx1emNkY3pncERqcUY4NlNMQ2JuY0tsWDFMT2ZTaFVhaUhZSDN6VVo4RE5tWVRyODNYX09IMWFiblczVzh0UFBFZXozejRMOUc4SHZGWDNMZ1FYd05LMzUzaDRDdV9hSEo2ZTZ4Z3dENmxhN2VadFhMdUticENVQU1tSDZobFhkRmtHRUxTLW9TNjZfNktYVXRwejNYLUcxWlE2eXpTV01OQjVXSjhGcGZkOXJkQnBhUndQSHBOdktUMlRGNkQ3TlljMnc?oc=5","date":"2026-02-04","type":"regulatory","source":"Reuters","summary":"GE HealthCare forecasts 2026 profit above estimates on strong demand for medical devices - Reuters","headline":"GE HealthCare forecasts 2026 profit above estimates on strong demand for medical devices","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxPVjZxb2tDTDJlQ0Y4akt0VjBFVG1NRG5mYTJleVNnNFgxZEF1THJqY3MzcU1Bdm85b3I2SmJPLWp6T3pDMkxLSFVuRnlQRnF2SThaMTkwTHBuZk00RW1raFpWdjRzclF2UHYxQ3FxanBKTFQzdjM0WjBFcVN6c1pVY0tJeUJjNWxJVXc?oc=5","date":"2026-01-30","type":"pipeline","source":"Yahoo Finance","summary":"Promising Prospects Expected in 2026 for GE HealthCare Technologies (GEHC) - Yahoo Finance","headline":"Promising Prospects Expected in 2026 for GE HealthCare Technologies (GEHC)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4AFBVV95cUxNYkgzcUtTQzlSNkE2XzMxQ2lfZnV4Tm9Zc21hTnlKZ0VTYVh4WVBlUGpRbnhDREpHZEg5YzFHa25heENQSHhDOUhteDVrU0toNF9xejRUZjdBVkp0dU9yUXNpc3pXUUVBZXh4SkpKZFRhZHZBangxQWFzdUUxbnRXVlZnTXRXdUR0OWs0MFpMcEFtX1RPNkhXMWctSWV2MDFEd1RJNG80RG1MbHZiVkg0QTZmYkFjTW9DX1JiZ1R0M1VIblFGaDBkNzVKMHYtXzNrWU9vNDNfanYzcWFoempubA?oc=5","date":"2025-12-07","type":"deal","source":"TechStock²","summary":"GE HealthCare Technologies Inc (GEHC): AI Imaging Surge, Intelerad Deal and 2026 Stock Forecasts – Latest News as of December 7, 2025 - TechStock²","headline":"GE HealthCare Technologies Inc (GEHC): AI Imaging Surge, Intelerad Deal and 2026 Stock Forecasts – Latest News as of Dec","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5wFBVV95cUxOeVJVMFVXV3VmajRJb3p0em1PZzV4M2pFd0FlTXhwQm81Tm5zQmlJY3F5SmNJN2dqZmNjRnFmbk40ZUU2OTl6Q0M5SENWUWpiMkZSVlBuU183WmVYelVrYXluUWtkNFk5Ym03bktVcndyeGRQY0JZdHV4NTh3dS1OeW9xYzRJV2FJdUxwS1l3YXJWSURqWGRxVy1ZR0EzelhkZmR0U2VEREZqakJFR3ZVSlNVbC0yTjJKcmstODdWczNBcFZMLUZCX25zajZab1B0bEhPbnRaS1ZkWndsQzFZV1JRVlpTT3M?oc=5","date":"2025-10-29","type":"regulatory","source":"Reuters","summary":"GE HealthCare boosts 2025 profit view after strong US demand helps third quarter - Reuters","headline":"GE HealthCare boosts 2025 profit view after strong US demand helps third quarter","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxNSzRkRG1BQVdPVVpvUzF0a0Vmd3YxMnREekw5aV9aSHc4dGY2SXZEbjl5Nl9HYk9QaE9uQXdRai01Wmk5b09jandPcHJOaXJ0RUZyek9zdjBIWWF3ZTZaRE1Rekd5UlMwenZWRF9EeU9SRUF3RnprRWhIQ2JwVFY1dVZrRW5jTmhtMGFEbUVVd2JyTm1HUTEyVml6c215aXNLY3l3?oc=5","date":"2025-10-29","type":"earnings","source":"TradingView","summary":"GE HealthCare Q3 2025 Financial Results - TradingView","headline":"GE HealthCare Q3 2025 Financial Results","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizwFBVV95cUxOb1VjNnI2QkEzZ3R4bkxJeF9JX3UtVkR3U0RtU3FOUU84R2o5WWZRNEhkbTlGdTlMY3pmUjZERjVzYVRxX2JLbDF3TUpfRFBmRzRqSi03cEE4cmdPWGJIOFgwSWlHeFBhY2ZjbDdudEhUdTJNNmVoVEZQczQ0WXBJZUdJSU40Zm85MVpZVHpwWk8ycjc0OUY3LW00WDIxYUw2Q1ByaEZGYzZ4ZkR1SUQwaS1URTZ5VDNNZ2hGamYyMFd0OXNqN1VWaVVvZUVfbTg?oc=5","date":"2025-10-29","type":"earnings","source":"The Globe and Mail","summary":"GE HealthCare (NASDAQ:GEHC) Surprises With Q3 Sales - The Globe and Mail","headline":"GE HealthCare (NASDAQ:GEHC) Surprises With Q3 Sales","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxQTFNkNEgxN0VGa19hNncySGRuN0pxUXF4cXZCX2Q5WXMtRUdzMDViclB0aC1sTUFzQkxuaGRuVGc5dDhabUpxU2lLTTQ5WVZxcnVrTXFzX2RBaVEzbGgzWThtZEtzOFE2U0hIaUJURFRrY2Z5blRXT3NMRzlraXNuRHpIZDluaHNud1RXek5ibWlMdDhsa1JuUC1Cc2kwZkRZTnFLNXJtLVN6ZGoyWWVwN0xNRURlT3NkQjVGaEpqN1NtR2dVSTNHNUJmb05IMlFtemczaEJCdFFkR2h0dXVlSktRR0xlU2RQWmc?oc=5","date":"2025-10-27","type":"earnings","source":"The Globe and Mail","summary":"Does GEHC Stock Deserve a Spot in Your Portfolio Ahead of Q3 Earnings? - The Globe and Mail","headline":"Does GEHC Stock Deserve a Spot in Your Portfolio Ahead of Q3 Earnings?","sentiment":"neutral"}],"patents":[{"drugName":"Perflutren Protein-Type A Microspheres Injectable Suspension","drugSlug":"perflutren-protein-type-a-microspheres","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":1200000000}],"drugCount":27,"phaseCounts":{"marketed":18,"phase_3":7,"phase_2":2},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["Siemens Healthineers","Philips Healthcare","Canon Medical Systems"],"therapeuticFocus":["Medical Imaging","Diagnostics"],"financials":{"source":"sec_edgar+yahoo","revenue":20625000000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":20625000000,"period":"2025-12-31"},{"value":19672000000,"period":"2024-12-31"},{"value":19672000000,"period":"2024-12-31"},{"value":19552000000,"period":"2023-12-31"},{"value":19552000000,"period":"2023-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":1260000000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":2084000000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":36906000000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":54000,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":73.05,"previousClose":69.73,"fiftyTwoWeekHigh":89.77,"fiftyTwoWeekLow":57.65,"fiftyTwoWeekRange":"57.65 - 89.77","fiftyDayAverage":76.88,"twoHundredDayAverage":76.83,"beta":1.3,"enterpriseValue":37970432000,"forwardPE":13.1,"priceToBook":3.21,"priceToSales":1.62,"enterpriseToRevenue":1.84,"enterpriseToEbitda":10.43,"pegRatio":1.67,"ebitda":3641999872,"ebitdaMargin":17.7,"freeCashflow":1687000064,"operatingCashflow":1987000064,"totalDebt":10462999552,"debtToEquity":98.7,"currentRatio":1.37,"returnOnAssets":5.5,"returnOnEquity":22.4,"analystRating":"1.9 - Buy","recommendationKey":"buy","numberOfAnalysts":19,"targetMeanPrice":92.79,"targetHighPrice":110,"targetLowPrice":75,"dividendRate":0.14,"payoutRatio":0.03,"fiveYearAvgDividendYield":0,"exDividendDate":1775088000,"insiderHeldPercent":0.3,"institutionHeldPercent":93.1,"sharesOutstanding":456290143,"floatShares":454487340,"sharesShort":11030659,"shortRatio":3.25,"shortPercentOfFloat":2.4,"epsTrailing":4.55,"epsForward":5.57,"revenuePerShare":45.23,"bookValue":22.77,"officers":[{"age":60,"name":"Mr. Peter J. Arduini","title":"President, CEO & Director"},{"age":52,"name":"Mr. James K. Saccaro","title":"VP & CFO"},{"age":53,"name":"Dr. Taha  Kass-Hout M.D., M.S.","title":"Chief Science & Technology Officer"},{"age":60,"name":"Mr. Frank R. Jimenez Esq.","title":"VP, General Counsel & Corporate Secretary"},{"age":53,"name":"Ms. Jeannette  Bankes","title":"President & CEO of Patient Care Solutions"},{"age":58,"name":"Mr. George Andrew Newcomb","title":"Controller & Chief Accounting Officer"},{"age":53,"name":"Mr. Jahidul H. Khandaker","title":"Chief Information Officer"},{"age":null,"name":"Ms. Carolynne  Borders","title":"Chief Investor Relations Officer"}],"industry":"Medical Devices","irWebsite":"","website":"https://www.gehealthcare.com","phone":"833 735 1139"}}